

**Table S1. Multivariate linear regression analysis for drug lag.**

Variable		Coefficient	Standard Error	Confidence interval	p-value
<b>Regulatory pathway in Korea</b>	New drug review by MFDS	reference			
	Orphan drug review by MFDS	25.012	7.4515	( 10.4071 - 39.6167 )	0.0008
<b>Nationality of the Marketing authorization holder (MAH)</b>	Non-Korean Company	reference			
	Korean Company	56.526	10.4251	( 36.0929 - 76.9585 )	<.0001
<b>Drug characteristics - Type of drug</b>	Chemical Drugs	reference			
	Biological Drugs	-2.126	8.84	( -19.4516 - 15.2005 )	0.81
<b>Drug characteristics - Therapeutic area</b>	non-oncology Drugs	reference			
	Oncology Drugs	-6.583	7.2312	( -20.756 - 7.5898 )	0.3626
<b>Nationality of pharmaceutical company for drug development</b>	USA	reference			
	Europe (including Switzerland)	-4.974	7.3202	( -19.321 - 9.3737 )	0.4969
	Japan	-2.235	12.7845	( -27.2919 - 22.8225 )	0.8612
	Others	-1.483	21.5827	( -43.7841 - 40.8185 )	0.9452
<b>Regulatory pathway in US</b>	Standard review by US FDA	reference			
	Priority review by US FDA	11.336	7.955	( -4.2551 - 26.9279 )	0.1541
<b>Approved year by MFDS</b>	Approved drugs before 2015	reference			
	Approved Drugs since 2015	-32.207	8.7913	( -49.438 - -14.9767 )	0.0002

**Table S2. Multivariate linear regression analysis on drug lag for non-orphan drugs related with clinical studies in Korea.**

Variable		Coefficient	Standard Error	Confidence interval	<i>p-value</i>
<b>Development lag from the initial clinical study to approval of the drug</b>		0.181	0.1196	( -0.0532 - 0.4156 )	0.1298
<b>Drug characteristics - Type of drug</b>	Chemical Drugs	reference			
	Biological Drugs	-3.960	4.4894	( -12.7592 - 4.8391 )	0.3777
<b>Drug characteristics - Therapeutic area</b>	non-oncology Drugs	reference			
	Oncology Drugs	14.958	3.7716	( 7.5653 - 22.3496 )	<.0001
<b>Nationality of pharmaceutical company for drug development</b>	USA	reference			
	Europe (including Switzerland)	-4.391	4.0055	( -12.242 - 3.4593 )	0.2729
	Japan	-9.404	7.0536	( -23.2286 - 4.4209 )	0.1825
<b>Regulatory pathway in US</b>	Standard review by US FDA	reference			
	Priority review by US FDA	-5.046	4.4423	( -13.7528 - 3.6605 )	0.256
<b>Number of clinical studies in Korea</b>		-6.429	2.3759	( -11.0856 - -1.7724 )	0.0068
<b>Number of Korean patients participated in clinical studies in Korea</b>		0.067	0.0253	( 0.0172 - 0.1162 )	0.0083